# Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects

> **NCT03905291** · PHASE1 · COMPLETED · sponsor: **Medy-Tox** · enrollment: 25 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MT921
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03905291
- **Lead sponsor:** Medy-Tox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-31
- **Primary completion:** 2018-12-26
- **Final completion:** 2018-12-26
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905291, "Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03905291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*